A Phase 4 interventional study of HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging and Two different doses of adenosine in Heart Failure and Reduced Ejection Fraction and Heart Failure, sponsored by Gødstrup Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Gødstrup Hospital · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Heart Failure, Systolic with a site in Denmark — 3 open to participants now, 6 under way, none of them phase 3. Heart Failure, Systolic · Denmark.
Among the 15 studies in Heart Failure, Systolic with a site in Denmark, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 4, and was the 15th registered.
230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.
Browse Heart Failure, Systolic studies →3 of the 15 studies in Heart Failure, Systolic with a site in Denmark are open now. Recruiting first, the newest first:
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
Bispebjerg Hospital · Sites in Denmark
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 60 across 165 interventional studies indexed under Heart Failure, Systolic.
Median enrollment 44 across the 11 interventional studies, 625 across the 4 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 8 most frequent:
Gødstrup Hospital is the lead sponsor of 24 studies on the registry; 14 are open to participants now.
Gødstrup Hospital has 1 study filed under Heart Failure, Systolic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Heart Failure, Systolic with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
Heart failure with reduced ejection fraction (HFrEF) is a heterogeneous condition with variable potential for left ventricular ejection fraction (LVEF) recovery. While LVEF improvement and reverse remodeling predict better outcomes, the determinants that predict left ventricular recovery remain poorly understood. An expert panel of the Journal of American College of Cardiology highlighted the need for improved HFrEF phenotyping to clarify recovery patterns and support personalized management and risk stratification.
Methods:
PRIMA-HF is a prospective prediction study designed to determine whether baseline cardiac multimodality imaging can predict LVEF recovery in patients with de novo HFrEF (n=180). The imaging protocol includes cardiac magnetic resonance (CMR), coronary computed tomography and [¹⁵O]H₂O positron emission tomography ([¹⁵O]H₂O-PET) and echocardiography. Patients will also undergo a six-minute walk test, blood volume measurement, and blood sampling. The primary outcome is the change in LVEF from baseline to approx. after 3-12 months (or after full optitration in GDMT), assessed by CMR.
In 60 patients from the PRIMA-HF cohort, the randomized, double-blind study High Dose Adenosine During Perfusion Imaging in Heart Failure (HAI-HF) will be conducted. HAI-HF evaluates whether high-dose adenosine (210 µg/kg/min) versus standard-dose (140 µg/kg/min) during [¹⁵O]H₂O-PET changes the stress myocardial blood flow, which is the primary endpoint.
Aim:
The PRIMA-HF study comprehensively characterizes patients with newly diagnosed HFrEF through multimodality imaging and systematically assesses change in LVEF using CMR. The study's deep phenotyping approach integrates clinical, imaging, biomarker, and functional data to capture disease heterogeneity, rather than relying on traditional measures such as LVEF or symptom class. This enables the identification of distinct patient subgroups with shared pathophysiological mechanisms.
The HAI-HF trial examines whether higher adenosine doses improve [¹⁵O]H₂O-PET perfusion imaging in HFrEF.
Together, the studies will advance understanding of myocardial recovery, improve perfusion assessment, and support development of a predictive model for HFrEF prognosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging · Drug: Two different doses of adenosine
Diagnostic Test: HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging · Drug: Two different doses of adenosine
HAI-HF: Patients will be randomized in a 1:1 ratio to one of two dosing sequences: high-dose followed by low-dose adenosine, or low-dose followed by high-dose adenosine.
Testing if high dose adenosine (210 ug/kg/min) during perfusion imaging results in a higher myocardial blood flow compared to standard dose (140 ug/kg/min) in patients with HFrEF
PRIMA-HF: Left ventricular ejection fraction (LVEF)
Change in LVEF (continuous variable, absolute change in LVEF in percent points)
Time frame: PRIMA-HF: Baseline through study completion, an average of 3 months
HAI-HF: Stress Myocardial Blood Flow (MBF)
Change in stress MBF (continuous variable, ml/min/g)
Time frame: Baseline and periprocedural
PRIMA-HF: Kansas City Cardiomyopathy Questionaire (KCCQ-12)
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) (points, continuous data)
Time frame: Baseline through study completion, an average of 3 months
PRIMA-HF: 6 minutes-walk-test
Change in 6MWT distance (meters, continuous data)
Time frame: Baseline through study completion, an average of 3 months
PRIMA-HF: Blood volume
Change in blodvolume (L, continuous data)
Time frame: Baseline through study completion, an average of 3 months
PRIMA-HF: NT-Pro-BNP
Change in NT-Pro-BNP (pg/mL or pmol/L, continuous data)
Time frame: Baseline through study completion, an average of 3 months
Plan to share: Yes — The study will adhere to all applicable regulations and guidelines governing the transfer of individual participantdata (IPD), which will be biological material (blood samples), abroad, ensuring that all data are handled confidentially and in full compliance with relevant legislation.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data sharing is planned after the enrollment of 200 patients in PRIMA-HF, which is anticipated to be achieved by the end of 2027. Approximately two months thereafter, we expect to have completed the necessary analyses, at which point the availability of individual participant data will cease. Upon completion of the project, collaborating partners will destroy all data in accordance with our agreements and applicable requirements.
Access criteria: We plan to send biological material for proteomics measurements for further analysis to either deCODE, Reykjavik, Iceland, or Olink, Uppsala, Sweden. This will only take place after legal approval has been obtained in the Central Denmark Region.
Started Dec 2025 (actual). Primary completion is estimated for Apr 2029, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gødstrup Hospital